Dosage Forms for Personalized Medicine: ...
Type de document :
Partie d'ouvrage: Chapitre
URL permanente :
Titre :
Dosage Forms for Personalized Medicine: From the Simple to the Complex
Auteur(s) :
Florence, Alexander T. [Auteur]
Siepmann, Juergen [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Siepmann, Juergen [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Titre de l’ouvrage :
Modern Pharmaceutics, Two Volume Set
Numéro :
189
Pagination :
493-511
Éditeur :
Taylor & Francis Group
Date de publication :
2010
Mention d’édition :
5th Edition
ISBN :
9780429148309
ISSN :
2154-5219
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
The basic ambition of personalized medicines is for patients to receive medications, which if not tailored for them as individuals, will be designed more specifically for them as part of a group of genetically, ...
Lire la suite >The basic ambition of personalized medicines is for patients to receive medications, which if not tailored for them as individuals, will be designed more specifically for them as part of a group of genetically, physiologically, or pathologically similar patients. This is in contrast to the current and frequently applied modus, which involves most patients receiving the same drug at the same dose and at the same frequency as others. There are of course exceptions to this. The postgenomic era in which we are purported to live has promised much, but has delivered less. The promise is that through a better understanding of pharmacogenetics and pharmacogenomics and through genetic profiling of patients especially those involved in clinical trials, more valuable data will become available to support the treatment of individuals and groups who are first likely to respond to the medication and/or be unlikely to suffer adverse reactions from its administration.Lire moins >
Lire la suite >The basic ambition of personalized medicines is for patients to receive medications, which if not tailored for them as individuals, will be designed more specifically for them as part of a group of genetically, physiologically, or pathologically similar patients. This is in contrast to the current and frequently applied modus, which involves most patients receiving the same drug at the same dose and at the same frequency as others. There are of course exceptions to this. The postgenomic era in which we are purported to live has promised much, but has delivered less. The promise is that through a better understanding of pharmacogenetics and pharmacogenomics and through genetic profiling of patients especially those involved in clinical trials, more valuable data will become available to support the treatment of individuals and groups who are first likely to respond to the medication and/or be unlikely to suffer adverse reactions from its administration.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Date de dépôt :
2023-05-30T09:54:03Z
2024-01-22T09:03:41Z
2024-01-22T09:03:41Z